Navigation Links
Optimer Pharmaceuticals and Astellas Announce Collaboration to Commercialize Fidaxomicin for Clostridium difficile infection (CDI) in Europe and Certain Other Countries in Middle East, Africa and CIS
Date:2/7/2011

SAN DIEGO & STAINES, England, Feb. 7, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) and Astellas Pharma Europe Ltd. ("Astellas") announced today the signing of an exclusive collaboration and license agreement to develop and commercialize fidaxomicin, an investigational antibiotic for CDI, in Europe and certain other countries in the Middle East, Africa and the Commonwealth of Independent States (CIS).

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

In return for an exclusive license to fidaxomicin in the territory, Astellas is obligated to pay Optimer an upfront cash payment of approximately $68 million.  Optimer is also eligible to receive additional cash payments totaling up to approximately $156 million upon the achievement of certain regulatory and commercial milestones.  Furthermore, Astellas is obligated to pay tiered double-digit royalty payments on net sales of fidaxomicin in the Territory.  Astellas will be responsible for all future costs associated with the development, manufacturing, and commercialization of fidaxomicin in the territory including the costs of the ongoing Marketing Authorization Application (MAA) with the European Medicines Agency (EMA).

"We believe the combined strengths of Astellas' world-class anti-infective business capabilities, including established relationships with payers and hospitals in Europe and certain other markets, combined with Optimer's novel therapeutic for CDI, represents the most effective way to address a serious, unmet health need," said Mr. Masao Yoshida, President and CEO of Astellas Pharma Europe Ltd.  "We look forward to bringing fidaxomicin to  these markets to help patients and providers address this serious life threatening disease."

"We expect the Astellas collabo
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... YORK , Sept. 2, 2014 Reportlinker.com ... in its catalogue: Asia - Pacific ... http://www.reportlinker.com/p02353212/Asia---Pacific-Minimally-Invasive-Surgery-Spinal-Device-Market.html The growth rate of ... spinal device market will remain at double-digit levels throughout ... surgeries as the future of this field. The ...
(Date:9/2/2014)... -- Perrigo Company plc, a public limited company incorporated under ... Company "), today announced that it is offering to exchange ... Senior Notes due 2016 (the " 2016 Exchange Notes "), ... " 2018 Exchange Notes "), $800,000,000 of its new 4.00% ... and $400,00,000 of its new 5.30% Senior Notes due 2043 ...
(Date:9/2/2014)... , Sept. 2, 2014  Ameritox SM , ... "A Deadly Trend: Prescription Drugs to Heroin," a research ... to heroin abuse, and examines deadly trends that have ... found here . The report ... of patients prescribed opioids. It examines five trends that ...
Breaking Medicine Technology:Asia - Pacific Minimally Invasive Surgery Spinal Device Market 2Asia - Pacific Minimally Invasive Surgery Spinal Device Market 3Asia - Pacific Minimally Invasive Surgery Spinal Device Market 4Asia - Pacific Minimally Invasive Surgery Spinal Device Market 5Asia - Pacific Minimally Invasive Surgery Spinal Device Market 6Asia - Pacific Minimally Invasive Surgery Spinal Device Market 7Asia - Pacific Minimally Invasive Surgery Spinal Device Market 8Asia - Pacific Minimally Invasive Surgery Spinal Device Market 9Asia - Pacific Minimally Invasive Surgery Spinal Device Market 10Perrigo Company plc Announces Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023 and 5.30% Senior Notes Due 2043 2Perrigo Company plc Announces Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023 and 5.30% Senior Notes Due 2043 3Perrigo Company plc Announces Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023 and 5.30% Senior Notes Due 2043 4Ameritox Research Report Reveals Pain Patients' Role in Current Heroin Epidemic 2
... Inc., a pharmaceutical company advancing orally-available antiviral therapeutics to ... President and Chief Executive Officer, will present at the ... 2011 at 3:00 p.m. ET at the Hilton New ... Mr. Moch will give an update on the company,s ...
... Codexis, Inc. (Nasdaq: CDXS ) today announced ... Officer and Senior Vice President, Process Development and Manufacturing, a ... Ph.D., President and Chief Executive Officer. Dr. ... DuPont. He served as Vice President, Research and Development for ...
Cached Medicine Technology:Chimerix to Present at the Citi 2011 Global Health Care Conference 2Chimerix to Present at the Citi 2011 Global Health Care Conference 3Codexis Names David Anton CTO & SVP, Process Development & Manufacturing 2
(Date:9/2/2014)... On August 30, 2014, Harper’s Bazaar ... You Should Wash Your Face .” According to ... population breathes air considered polluted by the World Health ... the skin’s pores destroying its natural oils. These oils ... that may cause cell damage, redness, aging skin ...
(Date:9/2/2014)... patients treated with lumpectomy followed by radiation therapy ... mastectomy, according to a large study conducted by ... and the Cancer Prevention Institute of California. , ... with the disease is the first to directly ... surgical interventions: bilateral mastectomy (the removal of both ...
(Date:9/2/2014)... 2, 2014 In a large population-based study ... that mild cognitive impairment (MCI) occurred twice more ... 2. Interestingly, this strong association was only observed ... participants (66-80 years) the association vanished. This study ... Disease . , The concept of MCI describes ...
(Date:9/2/2014)... within a few days of discharge do so principally because ... in other parts of the health care system, according to ... Annals of Emergency Medicine ( "Return Visits to the ... asked why they did not follow up as an outpatient, ... wait until their scheduled appointment or being instructed to return ...
(Date:9/2/2014)... 02, 2014 The Dream2Walk Foundation along with ... Sept. 14th, 2014 during Spinal Cord Injury Awareness Month featuring ... England, and Chuck Ligon. Linear Automotive will be there hosting ... , Doors open at 2pm. The car show is Pre ... free pass to the concert. There will be trophies for ...
Breaking Medicine News(10 mins):Health News:Simon Ourian, Kim Kardashian’s Doctor: Air Pollution May Be Aging Your Skin 2Health News:Breast cancer patients with bilateral mastectomy don't have better survival rates 2Health News:Breast cancer patients with bilateral mastectomy don't have better survival rates 3Health News:Breast cancer patients with bilateral mastectomy don't have better survival rates 4Health News:Diabetes mellitus and mild cognitive impairment: Higher risk in middle age? 2Health News:Discharged patients return to the ER because 'better safe than sorry' 2Health News:Gas Monkey Hosts Concert in Dallas Benefiting Dream2Walk Foundation with Linear Automotive 2
... Is it safe to wait to make a,decision about ... for all the doctor appointments and test results? Or ... Reassuring research,says that men can take the time they ... of Harvard Men,s Health Watch., One study evaluated ...
... and caregivers offers tips to families, friends, caregivers ... ... CHICAGO, Feb. 4 What do you say, what can you ... from a serious,disease? To kick-off National Patient Recognition Week, a week-long,observance ...
... More than half a million women around the world, ... natural family planning methods developed by Georgetown University Medical ... and thousands of others use CycleBeads a visual aid ... fertility to plan or prevent pregnancy. , Now ...
... York Methodist Hospital today announced the start of the ... multi-center clinical trial to explore an investigational treatment that ... suffering with advanced widespread emphysema. The study focuses on ... in the lung for trapped air to escape and ...
... the Stowers Institutes Trainor Lab has demonstrated that it can ... a gene implicated in the abnormality or by inhibiting its ... the Web site of the journal Nature Medicine yesterday, is ... cause of TCS. , The team evaluated how a ...
... Provide Insight ... 50+-year Relationships, MCLEAN, Va., Feb. 4 Sunrise Senior Living,(NYSE: ... services with,more than 450 communities worldwide, shared the results of a ... spent more than,five decades of special Valentine,s Days together., Sunrise ...
Cached Medicine News:Health News:Men Can Take Their Time to Decide on Prostate Cancer Treatment, Reports the Harvard Men's Health Watch 2Health News:It's National Patient Recognition Week - Here's How You Can Do Something Special for Someone Facing Illness 2Health News:It's National Patient Recognition Week - Here's How You Can Do Something Special for Someone Facing Illness 3Health News:CycleBeads help women manage their fertility 2Health News:New York Methodist Hospital to study airway bypass treatment for emphysema 2Health News:Trainor Lab prevents rare birth defect by inactivating p53 gene 2Health News:Secrets to Long-Lasting Marriages Revealed in Senior Survey 2Health News:Secrets to Long-Lasting Marriages Revealed in Senior Survey 3
... 3 year warranty Set one of ... for B.I.O. exam!, One touch auto return ... in 4 colors , Solid-State push button ... holder and transformer. , Electro-Magnetic counter-balanced slit ...
3.5v Standard Ophthalmoscope Set with Convertible Handle and Soft Case. Our Standard Ophthalmoscope Sets feature high-quality instruments, handles, and cases....
High-quality eyecare from the preferred name in diagnostic instruments....
Our 3.5v Streak or Spot Retinoscope Sets feature instruments with the brightest light output in the industry, reliable handles, and convenient cases....
Medicine Products: